Clinical Trial
Results Matter
Explore the effi cacy and safety data
at hcp.eliquis.com
NVAF
Indicated to reduce the risk of
stroke and systemic embolism
in patients with NVAF 1
NVAF: nonvalvular atrial fi brillation.
INDICATIONS
ELIQUIS is indicated to reduce the risk of stroke and systemic
embolism in patients with nonvalvular atrial fi brillation (NVAF).
ELIQUIS is indicated for the treatment of deep vein thrombosis
(DVT) and pulmonary embolism (PE), and to reduce the risk of
recurrent DVT and PE following initial therapy.
IMPORTANT SAFETY INFORMATION
WARNING: (A) PREMATURE DISCONTINUATION OF
ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS,
(B) SPINAL/EPIDURAL HEMATOMA
(A) Premature discontinuation of any oral anticoagulant,
including ELIQUIS, increases the risk of thrombotic events.
If anticoagulation with ELIQUIS is discontinued for a reason
other than pathological bleeding or completion of a course
of therapy, consider coverage with another anticoagulant.
(B) Epidural or spinal hematomas may occur in patients
treated with ELIQUIS who are receiving neuraxial anesthesia
or undergoing spinal puncture. These hematomas may result
in long-term o